Published in Cancer Lett on May 29, 2008
The burden of human papillomavirus infections and related diseases in sub-saharan Africa. Vaccine (2013) 1.18
The burden of HPV associated cancers in two regions in Nigeria 2012-2014. Cancer Epidemiol (2016) 0.75
Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res (2005) 11.52
High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol (2006) 5.86
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology (2004) 3.61
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol (2007) 3.38
Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer (2009) 3.33
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer (2006) 2.98
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol (2012) 2.41
Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell (2013) 2.35
Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol (2008) 2.32
Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg (2007) 2.30
Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res (2005) 2.28
GPR30 is overexpressed in post-puberal testicular germ cell tumors. Cancer Biol Ther (2011) 2.20
SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res (2005) 2.20
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res (2004) 2.17
Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res (2004) 1.99
30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ (2005) 1.97
Imatinib mesylate in chordoma. Cancer (2004) 1.94
TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J Clin Oncol (2010) 1.93
Phase II study of imatinib in advanced chordoma. J Clin Oncol (2012) 1.89
Conservative treatment of early endometrial cancer: preliminary results of a pilot study. Gynecol Oncol (2010) 1.87
Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene (2004) 1.82
Phylogeographic analysis of haplogroup E3b (E-M215) y chromosomes reveals multiple migratory events within and out of Africa. Am J Hum Genet (2004) 1.76
Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol (2009) 1.71
Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci U S A (2005) 1.70
Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics (2010) 1.68
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res (2010) 1.68
PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumors. Am J Surg Pathol (2008) 1.65
Chromosome band 17q21 in breast cancer: significant association between beclin 1 loss and HER2/NEU amplification. Genes Chromosomes Cancer (2010) 1.63
HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J Clin Oncol (2003) 1.61
A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up. Ann Surg (2005) 1.60
NeuroD1 expression in human prostate cancer: can it contribute to neuroendocrine differentiation comprehension? Eur Urol (2006) 1.59
BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene (2004) 1.58
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther (2009) 1.52
Peniscopically controlled CO2 laser excision for conservative treatment of in situ and T1 penile carcinoma: report on 224 patients. Eur Urol (2008) 1.49
KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res (2012) 1.49
Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. J Invest Dermatol (2009) 1.48
A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci U S A (2013) 1.44
Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res (2006) 1.44
Lack of SYT-SSX fusion transcripts in malignant peripheral nerve sheath tumors on RT-PCR analysis of 34 archival cases. Lab Invest (2002) 1.40
Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res (2009) 1.39
Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. Cancer Res (2005) 1.38
miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. Mol Cancer Res (2012) 1.38
Unusual myogenic and melanocytic differentiation of soft tissue pPNETs: an immunohistochemical and molecular study of 3 cases. Am J Surg Pathol (2010) 1.38
Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res (2006) 1.37
Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res (2006) 1.37
Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res (2006) 1.35
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med (2013) 1.31
Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol Cancer Ther (2010) 1.29
PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat (2008) 1.29
Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol (2009) 1.28
Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Arch (2012) 1.24
Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics (2013) 1.24
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother (2014) 1.23
HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression. Clin Cancer Res (2004) 1.23
UQCRH gene encoding mitochondrial Hinge protein is interrupted by a translocation in a soft-tissue sarcoma and epigenetically inactivated in some cancer cell lines. Oncogene (2003) 1.22
Integrative approach for prioritizing cancer genes in sporadic colon cancer. Genes Chromosomes Cancer (2009) 1.22
Polyomavirus BK-specific immunity after kidney transplantation. Transplantation (2004) 1.22
Novel and recurrent EVC and EVC2 mutations in Ellis-van Creveld syndrome and Weyers acrofacial dyostosis. Eur J Med Genet (2012) 1.21
Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin Cancer Res (2007) 1.21
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood (2003) 1.18
Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas. Am J Pathol (2010) 1.18
Identification of cripto-1 as a novel serologic marker for breast and colon cancer. Clin Cancer Res (2006) 1.18
Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensus PCR HPV-DNA, and In Situ Hybridization. Infect Agent Cancer (2012) 1.17
Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol Oncol (2011) 1.17
Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene (2004) 1.16
p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Clin Cancer Res (2003) 1.16
Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res (2008) 1.16
Familial transposition of the great arteries caused by multiple mutations in laterality genes. Heart (2009) 1.16
First-line treatment of advanced ovarian cancer: current research and perspectives. Expert Rev Anticancer Ther (2010) 1.15
Human melanoma metastases express functional CXCR4. Clin Cancer Res (2006) 1.15
HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur J Cancer (2008) 1.14
FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. Oncol Rep (2005) 1.14
Analysis of human papillomavirus type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer. J Med Virol (2004) 1.13
Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer. Clin Cancer Res (2004) 1.13
Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results. Int J Cancer (2005) 1.13
miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma. Oncotarget (2014) 1.12
High-grade sarcomatous overgrowth in solitary fibrous tumors: a clinicopathologic study of 10 cases. Am J Surg Pathol (2012) 1.11
Sclerosing polycystic adenosis of the parotid gland: report of one case diagnosed by fine-needle cytology with in situ malignant transformation. Diagn Cytopathol (2010) 1.11
Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. J Pathol (2004) 1.10
Is axillary lymph node dissection necessary in elderly patients with breast carcinoma who have a clinically uninvolved axilla? Cancer (2003) 1.10
Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol (2010) 1.09
New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study. Biotechnol Adv (2011) 1.09
Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma. Clin Cancer Res (2004) 1.08
Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. Int J Cancer (2011) 1.08
9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations. Cancer (2005) 1.07